TP53 and breast ductal adenocarcinoma: A comparison of Figure 3b and Figure 4b shows that ductal carcinomas contain hotspots and large MF measurements for PIK3CA mutation, whereas lung adenocarcinomas show hotspots and large MF measurements in EGFR, KRAS, TP53, and STK11. Although KRAS mutations were detected in ductal carcinomas, where they accounted for 12/537 (2%) of recovered mutations, KRAS mutations were more prevalent in lung adenocarcinomas, where they accounted for 58/470 (12%) of recovered mutations.